Nedosiran explored in primary hyperoxaluria type 3

The RNAi drug nedosiran is a once-monthly subcutaneous injection under investigation for all 3 types of primary hyperoxaluria.

Phase 3 trial will evaluate oncolytic immunotherapy for BCG-unresponsive NMIBC

“[Urologists are] very comfortable giving agents in the bladder, so [CG0070] really fits in line with what we give,” says investigator Edward Uchio, MD.

Nivolumab/cabozantinib combo nears EU approval for frontline kidney cancer

The European Commission is reviewing data from the pivotal phase 3 CheckMate-9ER trial.